9 reports

& nbsp; Emerging diagnostic technologies and their potential market applications.

  • Cancer
  • Cancer Diagnostic
  • Diagnostics
  • Spain
  • Demand
  • 3.4 FORECAST METHODOLOGY

[Accessed November ##, 2015].

  • Cancer
  • Lymphoma
  • Pathology
  • Spain
  • Forecast

& nbsp; Emerging diagnostic technologies and their potential market applications.

  • Cancer
  • Pathology
  • Spain
  • Demand
  • 3.4.7 Mutations (17p deletion, 11q Deletion, and TP53) Among the Diagnosed Incident Cases of CLL

LEUKEMIA; ##(##):##-##.

  • Cancer
  • Epidemiology
  • Hospital
  • Leukemia
  • Spain

STILL, PSA TESTING REMAINS A WIDELY AVAILABLE DIAGNOSTIC OPTION.

  • Cancer
  • Pathology
  • Prostate Cancer
  • Spain
  • Forecast
  • Prognostic Test - Colorectal Cancer - Product Status
  • Sep 14, 2011: Oryzon Genomics To Launch GynEC Dx Non Invasive Test For Detection Of Endometrial Cancer

From 2008 to 2010, Dr Greig was also President of SR One, GSK' s Corporate Venture Group.

  • Cancer
  • Genomics
  • Spain
  • Company
  • Oryzon Genomics S.A.
  • 05/06/2016: EARLY DIAGNOSIS, A MULTIDISCIPLINARY APPROACH AND ACCESS TO NEW THERAPIES, KEY IN THE TREATMENT OF OVARIAN CANCER

The exchange ratio between the shares of the two companies was ##:##, one Pharma Mar share for each Zeltia share.

  • Cancer
  • Pharmaceutical
  • Spain
  • Company
  • Pharma Mar, S.A.

(Roche) is a research-focused healthcare company that provides biopharmaceuticals, cancer medicines and in vitro diagnostics (IVD) systems.

  • Cancer
  • Spain
  • World
  • Product Initiative
  • Oryzon Genomics S.A.

Oxford Immunotec Global Plc (OIG) is a global, commercial-stage diagnostics company.

  • Cancer
  • Healthcare
  • Pharmaceutical
  • Therapy
  • Spain